Skip to content

Asset turnover at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
0.4×0.0×
Bausch + Lomb logo
Bausch + LombBLCO
0.4×0.0×
HRO
HarrowHROW
0.7×0.0×
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
+0.4×
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
0.5×+0.1×
PBH
Prestige Consumer HealthcarePBH
0.3×0.0×

Other financials

Income statement

See full
Revenue$10.8M+0.8%
Gross profit$9.5M+0.2%
Operating income-$93.3M-46.0%
Net income-$88.6M-38.3%
EPS (diluted)-$0.40-5.3%

Balance sheet

See full
Cash & equivalents$666.7M+90.7%
Total debt$79.5M+4.2%
Total equity$581.6M+119%
Total assets$732.5M+80.5%

Cash flow

See full
Operating cash flow-$66.0M-47.7%
CapEx$4.7M+141%
Free cash flow-$70.7M-51.6%

Valuation

See full
Market cap$2.21B+58.2%
Enterprise value$1.63B+40.8%
P/S42.6×+19.1×

Profitability

See full
Gross margin87.2%-3.4pp
Operating margin-575.4%+1,233pp
Net margin-558.2%+1,493pp
FCF margin-463%+2,860pp

Returns & leverage

See full
Return on equity-68.6%+17.0pp
Debt / equity0.1×-0.2×
Current ratio14.8×+4.6×

Where this comes from

Calculated from Ocular Therapeutix’s reported figures.

Based on trailing twelve months.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's asset turnover.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ocular Therapeutix's asset turnover?
Ocular Therapeutix (OCUL) reported asset turnover of 0.1× in Q1 2026.
How has Ocular Therapeutix's asset turnover changed year-over-year?
Ocular Therapeutix's asset turnover decreased by 27.6% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Ocular Therapeutix's asset turnover?
Over 5 years (2020 to 2025), Ocular Therapeutix's asset turnover has grown at a -4.3% compound annual growth rate (CAGR), from 0.1× to 0.1×.
What does asset turnover mean?
Trailing-twelve-month revenue divided by average total assets. Measures how many dollars of sales each dollar of assets generates — the efficiency leg of the DuPont decomposition of ROE.